Balchem

US · BCPC #2068 by market cap Listed 1970

166.41 +1.12 +0.68%

Live - 5344 symbols - heartbeat 256s ago · 2026-10-07 19:54

After-hours 166.41 0.00%

Market cap: 5.30B
P/E (TTM): 32.76
P/B: 4.07
EPS: 4.75
Div yield: 0.58%
52W pos: 60%

Reader sentiment Are you bullish or bearish on BCPC?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 9.51, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +8.75% YoY

Margins

Gross margin: 35.74%
Operating margin: 20.18%
Net margin: 14.93%

Key ratios & quality

Enterprise value: 5.40B
PEG ratio: 2.39
Altman Z-Score: 9.51

PEG uses trailing P/E against the 3-year net income growth rate (13.69%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	643.68M	643.71M	703.64M	799.02M	942.36M	922.44M	953.68M	1.04B
Gross profit	204.25M	211.37M	223.90M	243.17M	280.45M	302.06M	336.21M	370.63M
Selling & admin expenses	85.56M	97.44M	102.42M	102.15M	123.07M	127.81M	136.50M	142.80M
Research & development	11.59M	11.38M	10.33M	13.52M	12.19M	15.05M	16.79M	18.51M
Operating profit	107.10M	102.55M	111.15M	127.50M	145.19M	159.19M	182.91M	209.33M
Pretax profit	99.03M	96.48M	106.42M	125.23M	133.75M	137.26M	166.45M	199.03M
Tax	20.46M	16.81M	21.79M	29.13M	28.38M	28.72M	37.98M	44.19M
Net profit	78.57M	79.67M	84.62M	96.10M	105.37M	108.54M	128.48M	154.85M
Basic EPS	2	2	3	3	3	3	4	5
Diluted EPS	2.42	2.45	2.60	2.94	3.25	3.35	3.93	4.75

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	250.52M	255.47M	267.56M	263.62M	270.71M	284.00M
Gross profit	88.17M	93.11M	95.45M	93.90M	101.08M	103.68M
Selling & admin expenses	32.49M	37.37M	36.38M	36.56M	39.58M	39.93M
Research & development	4.66M	4.30M	4.50M	5.05M	5.88M	4.53M
Operating profit	51.02M	51.44M	54.58M	52.29M	55.63M	59.22M
Pretax profit	47.94M	49.01M	52.04M	50.04M	52.52M	57.78M
Tax	10.89M	10.73M	11.76M	10.81M	12.24M	13.17M
Net profit	37.05M	38.28M	40.29M	39.23M	40.29M	44.62M
Basic EPS	1	1	1	1	1	1
Diluted EPS	1.13	1.17	1.24	1.21	1.25	1.39

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	226.31M	254.95M	266.89M	322.23M	335.80M	314.24M	313.77M	365.61M
Cash & ST investments	54.27M	65.67M	84.57M	103.24M	66.56M	64.45M	49.52M	74.57M
Inventory	67.19M	83.89M	70.62M	91.06M	119.67M	109.52M	130.80M	131.45M
Total assets	981.36M	1.16B	1.17B	1.20B	1.62B	1.60B	1.58B	1.69B
Total current liabilities	82.06M	92.26M	94.43M	143.80M	140.04M	148.49M	157.69M	176.38M
Short-term debt	--	2.48M	2.34M	2.36M	4.02M	4.22M	3.33M	3.82M
Long-term debt	156.00M	248.57M	163.57M	108.57M	440.57M	309.57M	190.00M	164.00M
Total liabilities	289,737,000.00	412,015,000.00	337,610,000.00	322,310,000.00	686,228,000.00	543,227,000.00	425,458,000.00	428,839,000.00
Total equity	691.62M	743.67M	828.23M	877.02M	938.28M	1.05B	1.15B	1.26B
Retained earnings	528.03M	590.92M	656.74M	732.14M	814.49M	897.49M	997.49M	1.12B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	340.24M	364.86M	343.72M	365.61M	388.94M	388.42M
Cash & ST investments	49.90M	65.43M	65.09M	74.57M	72.87M	63.17M
Inventory	144.93M	148.15M	132.44M	131.45M	146.74M	161.55M
Total assets	1.62B	1.68B	1.66B	1.69B	1.69B	1.69B
Total current liabilities	139.56M	138.14M	126.37M	176.38M	152.54M	145.76M
Short-term debt	3.92M	3.87M	4.15M	3.82M	3.65M	3.38M
Long-term debt	190.00M	190.00M	154.00M	164.00M	169.00M	152.00M
Total liabilities	408,854,000.00	410,334,000.00	363,167,000.00	428,839,000.00	408,626,000.00	384,626,000.00
Total equity	1.21B	1.27B	1.30B	1.26B	1.29B	1.30B
Retained earnings	1.03B	1.07B	1.11B	1.12B	1.16B	1.21B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	118.70M	124.46M	150.49M	160.51M	138.54M	183.76M	182.00M	216.56M
Depreciation & amortization	44.67M	45.86M	51.28M	48.88M	51.85M	54.94M	47.97M	45.69M
Free cash flow	98.97M	96.05M	116.67M	123.15M	88.59M	145.87M	146.34M	173.07M
Dividends paid	-13.43M	-15.14M	-16.71M	-18.72M	-20.71M	-22.87M	-25.58M	-28.29M
Stock buybacks / issuance	-1.39M	-21.32M	-13.46M	-35.24M	-35.42M	-4.47M	-5.68M	-107.64M
Ending cash balance	54.27M	65.67M	84.57M	103.24M	66.56M	64.45M	49.52M	74.57M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	36.46M	47.25M	65.57M	67.28M	40.06M	46.71M
Depreciation & amortization	11.01M	11.40M	11.55M	11.72M	12.49M	12.22M
Free cash flow	30.90M	40.44M	50.67M	51.06M	33.81M	35.83M
Dividends paid	-28.26M	-2.00K	-11.00K	-11.00K	-30.77M	-3.00K
Stock buybacks / issuance	-5.33M	-33.26M	-15.42M	-53.63M	-15.69M	-28.79M
Ending cash balance	49.90M	65.43M	65.09M	74.57M	72.87M	63.17M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	12.01	11.10	10.77	11.27	11.61	10.90	11.66	12.86
ROA %	8.08	7.46	7.29	8.13	7.46	6.74	8.10	9.50
ROIC %	10.27	9.15	8.82	9.82	9.48	9.09	10.30	11.64
5-year avg ROE %	13.56	12.85	12.22	12.20	11.35	11.13	11.24	11.66
EBIT margin %	16.57	15.91	15.75	15.98	15.28	17.33	19.19	20.18
FCF / sales %	15.38	14.92	16.58	15.40	9.36	15.81	15.34	16.69
Current ratio	2.76	2.76	2.83	2.24	2.40	2.12	1.99	2.07
Quick ratio	1.87	1.72	1.94	1.53	1.41	1.28	1.07	1.24
Debt / assets	15.90	22.14	14.75	9.84	28.35	20.68	13.21	10.72
LT debt / equity	22.56	34.07	20.48	13.19	48.66	30.94	17.80	14.07
Interest coverage	14.01	17.19	24.97	51.99	14.03	7.07	11.07	20.48
Revenue CAGR (3Y) %	5.22	5.18	5.76	7.47	13.55	9.44	6.08	3.25
Net income CAGR (3Y) %	9.58	12.49	-2.06	6.94	9.77	8.65	10.16	13.69
FCF CAGR (3Y) %	17.18	4.73	12.24	7.56	-2.66	7.73	5.92	25.01

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	11.94	11.99	12.06	12.86	12.68	12.79
ROA %	8.52	8.78	9.16	9.50	9.55	9.77
ROIC %	10.46	10.61	10.91	11.64	11.46	11.62
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	19.86	20.07	20.19	20.18	20.16	20.36
FCF / sales %	15.63	15.53	15.94	16.69	16.64	15.78
Current ratio	2.44	2.64	2.72	2.07	2.55	2.66
Quick ratio	1.29	1.46	1.56	1.24	1.49	1.46
Debt / assets	12.86	12.37	10.35	10.72	10.91	9.88
LT debt / equity	16.89	16.07	12.93	14.07	14.09	12.54
Interest coverage	13.63	15.73	18.37	20.48	22.41	25.47
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Human Nutrition and Health (HNH) is the largest reported line at 62.29% of revenue, across 4 reported segments.
Animal Nutrition and Health (ANH) follows at 22.70%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Human Nutrition and Health (HNH)62.29%

Animal Nutrition and Health (ANH)22.70%

Specialty Products (SP)14.26%

Other and Unallocated0.75%

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.